048410 — Hyundai Bioscience Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeMid CapSucker Stock

Annual income statement for Hyundai Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	30,086	12,511	9,241	7,852	9,481
Cost of Revenue
Gross Profit	14,122	6,563	3,521	2,683	5,041
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	27,531	19,880	26,529	25,840	24,035
Operating Profit	2,555	-7,369	-17,287	-17,989	-14,554
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,294	-7,933	-19,808	-16,613	-14,498
Provision for Income Taxes
Net Income After Taxes	1,215	-8,260	-20,051	-15,807	-14,499
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	767	-8,260	-20,051	-15,807	-14,499
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	767	-8,260	-20,051	-15,807	-14,499
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	35.2	-179	-411	-540	-287
Dividends per Share